Abstract:IntroductionEndothelial progenitor cells (EPC) capable of initiating or augmenting vascular growth were recently identified within the small population of CD34-expressing cells that circulate in human peripheral blood and which are considered hematopoietic progenitor cells (HPC). Soon thereafter human HPC began to be used in clinical trials as putative sources of EPC for therapeutic vascular regeneration, especially in myocardial and critical limb ischemias. However, unlike HPC where hematopoietic efficacy is related quantitatively to CD34+ cell numbers implanted, there has been no consensus on how to measure EPC or how to assess cellular graft potency for vascular regeneration. We employed an animal model of spontaneous neovascularization to simultaneously determine whether human cells incorporate into new vessels and to quantify the effect of different putative angiogenic cells on vascularization in terms of number of vessels generated. We systematically compared competence for therapeutic angiogenesis in different sources of human cells with putative angiogenic potential, to begin to provide some rationale for optimising cell procurement for this therapy.MethodsHuman cells employed were mononuclear cells from normal peripheral blood and HPC-rich cell sources (umbilical cord blood, mobilized peripheral blood, bone marrow), CD34+ enriched or depleted subsets of these, and outgrowth cell populations from these. An established sponge implant angiogenesis model was adapted to determine the effects of different human cells on vascularization of implants in immunodeficient mice. Angiogenesis was quantified by vessel density and species of origin by immunohistochemistry.ResultsCD34+ cells from mobilized peripheral blood or umbilical cord blood HPC were the only cells to promote new vessel growth, but did not incorporate into vessels. Only endothelial outgrowth cells (EOC) incorporated into vessels, but these did not promote vessel growth.ConclusionsThese studies indicate that, since EPC are very rare, any benefit seen in clinical trials of HPC in therapeutic vascular regeneration is predominantly mediated by indirect proangiogenic effects rather than through direct incorporation of any rare EPC contained within these sources. It should be possible to produce autologous EOC for therapeutic use, and evaluate the effect of EPC distinct from, or in synergy with, the proangiogenic effects of HPC therapies.

Isolation-protocol, characterization, and in-vitro performance of equine umbilical vein endothelial cells

Equine Endothelial Cells Show Pro-Angiogenic Behaviours in Response to Fibroblast Growth Factor 2 but Not Vascular Endothelial Growth Factor A

Human and equine endothelial cells in a live cell imaging scratch assay in vitro.

Improved Isolation, Culture and Identification of Vascular Endothelial Cells from Human Umbilical Veins in Vitro

Systematic assessment in an animal model of the angiogenic potential of different human cell sources for therapeutic revascularization

Culture and Characterization of Endothelial Progenitor Cells from Peripheral Blood of Rabbits

A Modified Method for the Isolation and Cultivation of Primary Human Umbilical Vein Endothelial Cell

The Cultivation Refrigerated Storage Revivification and Identification of Human Umbilical Vein Endothelial Cells

Replacement in angiogenesis research: Studying mechanisms of blood vessel development by animal-free in vitro, in vivo and in silico approaches

Cell Engraftment, Vascularization, and Inflammation after Treatment of Equine Distal Limb Wounds with Endothelial Colony Forming Cells Encapsulated Within Hydrogel Microspheres

[Isolation, Culture and Characterization of Outgrowth Endothelial Cells from the Human Peripheral Blood].

Experimental study on culture method of human umbilical vein endothelial cells]

3D artificial round section micro-vessels to investigate endothelial cells under physiological flow conditions

Isolation and culture of endothelial progenitor cells from feline bone marrow

Comparison of Sources and Methods for the Isolation of Equine Adipose Tissue-Derived Stromal/Stem Cells and Preliminary Results on Their Reaction to Incubation with 5-Azacytidine

Use of Human Umbilical Vein Endothelial Cells (HUVEC) as a Model to Study Cardiovascular Disease: A Review

Study on Immortalization of Swine Umbilicus Veins Endothelial Cells

In Vitro and in Vivo Study on Angiogenesis of Porcine Induced Pluripotent Stem Cell-Derived Endothelial Cells.

De novo reconstruction of a functional in vivo-like equine endometrium using collagen-based tissue engineering

In Vivo Perfusion of Porcine Kidney Scaffolds Re-Endothelialized with Human Umbilical Vein Endothelial Cells

Encapsulation of Equine Endothelial Colony Forming Cells in Highly Uniform, Injectable Hydrogel Microspheres for Local Cell Delivery.